Panagiota Papadopoulou

Marie Skłodowska- Curie Postdoctoral Fellow National Hellenic Research Foundation

Panagiota Papadopoulou holds a PhD in Bionanotechnology from Leiden University (the Netherlands), where she specialized in lipid nanoparticle design and structure–function relationships in biological environments.

Currently, she is a Marie Skłodowska-Curie Postdoctoral Fellow at the National Hellenic Research Foundation (Athens, Greece), investigating the ultrastructure, intracellular trafficking, and endosomal escape of RNA-LNPs. Her research focuses on linking lipid composition, morphology, and structural integrity to biological fate, using advanced cryo-electron microscopy at the first cryo-EM facility in Greece (cryoUNITe).

Previously, she was a Postdoctoral Researcher at Leiden University, in collaboration with the Netherlands Cancer Institute, where she worked on liposomal and RNA-LNP therapeutics for glioblastoma, contributing to high EU-funded scientific projects (ERC-Synergy). She remains engaged as an external scientific consultant for both organizations.

Seminars

Wednesday 23rd September 2026
Visualising & Engineering Intracellular LNP Behaviour: Unlocking Endosomal Escape & Cell-Specific Targeting
11:40 am
  • Map intracellular LNP structure and integrity using advanced cryo-EM imaging
  • Investigate endosomal escape mechanisms under physiologically relevant conditions
  • Link nanoparticle morphology and phase behavior to cell-specific targeting outcomes
  • Generate early in vitro and in vivo insights to inform rational LNP design beyond trial-and-error
Wednesday 23rd September 2026
Closing Simulation Exercise: Work Through Real World Scenarios to Successfully Take an LNP Therapy from Concept to Clinic
4:30 pm

A practical, end-to-end simulation where participants work through the full lifecycle of an LNP therapy, integrating innovation, CMC and regulatory decision-making to successfully move a candidate toward clinical readiness.

  • A practical framework for evaluating LNP designs beyond scientific performance
  • Clear understanding of how CMC and regulatory constraints reshape innovation
  • Improved ability to make phase-appropriate decisions that accelerate timelines
  • Real insight into where most LNP programs fail or stall before clinic
Panagiota Papadopoulou